Neurizon Therapeutics Limited has released a press release.
PharmAust Receives $700k R&D Tax Incentive Refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Epichem Awarded One-Year Contract Extension from DNDi
- Epichem client gives notice to end contract in February 2020
- Expanded Site Recruitment for Phase II MPL Dog Cancer Trial
- Presentation - Pitt Street Research Life Sciences Conference
- Progress in Recruitment for Phase II Trial in Dogs
Later from Neurizon Therapeutics
- Brisbane Animal Hospital Joins Phase II Dog Cancer Trial
- PharmAust to Evaluate Monepantel on COVID-19
- Monepantel Trial Achieves Successful Anti-Cancer Outcome
- Suspension from Official Quotation
- Preliminary Positive Results for the Treatment of SARS-CoV-2
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics